Five new chromane meroditerpenoids from the brown alga Sargassum siliquastrum of China Sea

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-11-06 DOI:10.1016/j.phytol.2024.11.001

Junzhi Pan , Huayuan Liu , Junpeng Xu , Xiaofeng Xu , Yu Qi , Chaojie Wang , Changle Wu , Zhongmin Sun , Yali Lv , Pengcheng Yan

引用次数: 0

Abstract

Five previously undescribed chromane-type meroditerpenoids, sargasilols J–N (1–5), were isolated from an EtOAc-soluble extract of the brown alga Sargassum siliquastrum collected in the China Sea. The chemical structures of these meroditerpenoids were determined by extensive spectroscopic analyses, including 1D/2D NMR, ECD, and HR-ESI-MS data. Compound 3 exhibited potent anti-neuroinflammatory activity against lipopolysaccharide (LPS)-induced nitric oxide (NO) production in BV-2 microglia cells, with an IC₅₀ value of 9.9 μM.

查看原文本刊更多论文

中国海褐藻马尾藻中的五种新的色烷经二萜类化合物

从中国海采集的褐藻马尾藻（Sargassum siliquastrum）的乙醇萃取物中分离出了五种以前未曾描述过的色烷型经二萜类化合物--马尾藻醇 J-N (1-5)。通过广泛的光谱分析，包括 1D/2D NMR、ECD 和 HR-ESI-MS 数据，确定了这些经二萜化合物的化学结构。化合物 3 在 BV-2 小胶质细胞中对脂多糖（LPS）诱导的一氧化氮（NO）生成具有强效的抗神经炎活性，IC50 值为 9.9 μM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.